News Sentiment

RVMD sentiment intelligence

Revolution Medicines Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 60 Balanced news tone 62 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 186.16 Week of 17 Jul 2026
Weighted tone 60/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

77/100 classification confidence.

Company focus 53

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend active

-0.4% over one week, +14.2% over four weeks, trend active, and materially above fair value.

Latest direct headline Neutral

Revolution Medicines, Inc. (RVMD) Q3 2024 Earnings Report - Results, Call & Slides

Market Reaction

Balanced read

59/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 77/100 classification
One-week reaction -0.4% Price digesting
Trend fit Trend active 14.2% over four weeks
Fair value 227.8% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 27
Neutral 31
Negative 4

Relevance

Why the article matched

Direct first
Direct company coverage 53
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 13
Stock Titan 7
Simply Wall Street 5
MT Newswires 4
TradingView 4
Quiver Quantitative 3
Investing.com 3
simplywall.st 3

Event Lens

What the news is about

Classified themes
Market update 28
Earnings 22
Analyst action 5
Regulatory and legal 4
Deals and strategy 3

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 62
Simply Wall Street Direct company coverage

Is Revolution Medicines (RVMD) A Bargain As Daraxonrasib Trial Results Lift Its Outlook?

Revolution Medicines (RVMD) is under scrutiny after positive Phase III results for Daraxonrasib and new FDA designations, boosting its stock price significantly. While Simply Wall St's narrative suggests the stock is 39.2% overvalued at $186.16 compared to a fair value of $133.70

Tone
Positive 72/100
Event
Earnings
Published
19 Jul 2026 17:10
Source
Simply Wall Street
Quiver Quantitative Direct company coverage

Revolution Medicines Gains as Investors Continue to Digest Clinical and Regulatory Momentum

Revolution Medicines (RVMD) saw a 3.1% increase, likely due to continued positive investor sentiment surrounding its pancreatic cancer pipeline. This sentiment follows favorable clinical data updates and a new European regulatory step for daraxonrasib in early July, alongside rai

Tone
Positive 71/100
Event
Regulatory and legal
Published
17 Jul 2026 17:35
Source
Quiver Quantitative
Simply Wall Street Direct company coverage

How Investors Are Reacting To Revolution Medicines (RVMD) Pancreatic Cancer Data For RAS G12D Inhibitor

Revolution Medicines reported promising Phase 1/2 data for its RAS(ON) G12D inhibitor, zoldonrasib, in metastatic pancreatic cancer, showing high response rates and manageable safety. These early results are crucial as there are no approved targeted therapies for RAS G12D cancers

Tone
Positive 63/100
Event
Earnings
Published
14 Jul 2026 10:40
Source
Simply Wall Street
Moomoo Direct company coverage

Revolution Medicines Price Target Raised to $235.00/Share From $205.00 by Guggenheim

Guggenheim has increased its price target for Revolution Medicines (NASDAQ:RVMD) to $235.00 per share, up from the previous target of $205.00. This revision suggests a strong positive outlook on the company's future performance. Potential investors should consider this updated va

Tone
Positive 72/100
Event
Analyst action
Published
09 Jul 2026 20:39
Source
Moomoo
Quartr Direct company coverage

Revolution Medicines (RVMD) Investor Update Summary

Revolution Medicines (RVMD) has announced a significant strategic partnership with Royalty Pharma, securing up to $2 billion in funding without equity dilution, which will support independent global development and commercialization of its RAS(ON) inhibitor portfolio. The company

Tone
Positive 76/100
Event
Deals and strategy
Published
08 Jul 2026 21:11
Source
Quartr
Simply Wall Street Direct company coverage

Revolution Medicines (RVMD) Wins Faster Reviews, Is The Valuation Already Too Rich?

Revolution Medicines (RVMD) is under scrutiny after its drug daraxonrasib received accelerated review for pancreatic cancer and partner drug zoldonrasib showed early trial results. Despite a significant recent share price surge, a common valuation narrative suggests RVMD is 42.5%

Tone
Negative 40/100
Event
Earnings
Published
08 Jul 2026 20:28
Source
Simply Wall Street
GlobeNewswire Direct company coverage

European Medicines Agency Expedites Assessment of Revolution Medicines’ Daraxonrasib Under Phased Review Process

The European Medicines Agency (EMA) has initiated a phased review of daraxonrasib, Revolution Medicines’ investigational drug for pancreatic cancer, aiming to accelerate its assessment based on promising Phase 3 trial results. Simultaneously, Revolution Medicines is nearing compl

Tone
Positive 74/100
Event
Regulatory and legal
Published
07 Jul 2026 21:11
Source
GlobeNewswire
Quiver Quantitative Direct company coverage

Revolution Medicines Says EMA Begins Phased Review of Daraxonrasib for Pancreatic Cancer as FDA NDA Submission Nears Completion

Revolution Medicines announced the European Medicines Agency (EMA) has initiated a phased review of its investigational drug, daraxonrasib, for pancreatic cancer, following positive Phase 3 trial results. The drug, designated as an orphan medicinal product by the EMA and a priori

Tone
Positive 73/100
Event
Regulatory and legal
Published
07 Jul 2026 13:31
Source
Quiver Quantitative
Stock Titan Direct company coverage

EMA fast-tracks Revolution Medicines' pancreatic cancer drug review

The European Medicines Agency (EMA) has initiated a phased review of Revolution Medicines' investigational drug, daraxonrasib, for pancreatic cancer to expedite its assessment before a full marketing authorization application. This decision is based on positive Phase 3 data from

Tone
Positive 81/100
Event
Regulatory and legal
Published
07 Jul 2026 13:11
Source
Stock Titan
Investing.com South Africa Direct company coverage

Revolution Medicines stock hits all-time high at 193.12 USD By Investing.com

Revolution Medicines Inc. stock has reached an all-time high of $193.12, trading just 1% below its 52-week high, marking a significant 424.05% increase over the past year despite being deemed overvalued by InvestingPro. This surge follows positive Phase 1/2 clinical trial results

Tone
Positive 72/100
Event
Earnings
Published
06 Jul 2026 14:41
Source
Investing.com South Africa
The Globe and Mail Direct company coverage

Revolution Medicines Is Up Nearly 140% in 2026. Is the Hot Biotech Stock Still a Buy?

Revolution Medicines (NASDAQ: RVMD) has seen its stock price surge by nearly 140% in 2026 due to promising late-stage clinical trial results for its cancer treatments, which target previously "undruggable" RAS proteins. The company's lead candidate, daraxonrasib, has shown signif

Tone
Positive 66/100
Event
Earnings
Published
06 Jul 2026 07:41
Source
The Globe and Mail
Simply Wall Street Direct company coverage

Will Strong Early Zoldonrasib Pancreatic Data Change Revolution Medicines' (RVMD) RAS-Focused Narrative?

Revolution Medicines reported positive Phase 1/2 data for its oral RAS(ON) G12D inhibitor zoldonrasib in pancreatic cancer, showing high response rates and manageable safety in combination with other treatments. These results support ongoing and planned global Phase 3 trials, str

Tone
Positive 72/100
Event
Earnings
Published
06 Jul 2026 06:39
Source
Simply Wall Street
Kavout | AI Direct company coverage

Revolution Medicines: A $40 Billion Bet on a Cancer Breakthrough, But At What Price?

Revolution Medicines (NASDAQ: RVMD) has seen its market capitalization surge to $40.23 billion due to groundbreaking Phase 3 trial results for its lead cancer drug, daraxonrasib, which showed unprecedented efficacy in metastatic pancreatic cancer. Despite having no revenue and co

Tone
Positive 82/100
Event
Earnings
Published
06 Jul 2026 05:41
Source
Kavout | AI
TradingView Direct company coverage

Revolution Medicines, Inc. Warrant Financial Disclosures & SEC Filings

This page provides access to Revolution Medicines, Inc. (RVMDW) financial disclosures and SEC filings, including Forms 10-K, 10-Q, 8-K, and other key documents. The filings highlight significant company events such as study results for Daraxonrasib, quarterly earnings, and partic

Tone
Neutral 50/100
Event
Earnings
Published
05 Jul 2026 07:10
Source
TradingView
GlobeNewswire Direct company coverage

Revolution Medicines Presents Phase 1/2 Clinical Data for Zoldonrasib Combination Regimens in Patients with RAS G12D Metastatic Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026

Revolution Medicines, Inc. announced promising Phase 1/2 clinical data for zoldonrasib combination regimens in patients with RAS G12D metastatic pancreatic cancer. The results, presented at the ESMO Gastrointestinal Cancers Congress 2026, show compelling efficacy and manageable s

Tone
Positive 93/100
Event
Earnings
Published
03 Jul 2026 06:39
Source
GlobeNewswire
The Clinical Trial Vanguard Direct company coverage

Revolution Medicines Reports 82% Response Rate for Zoldonrasib in Metastatic Pancreatic Cancer

Revolution Medicines presented promising Phase 1/2 data for zoldonrasib in metastatic pancreatic ductal adenocarcinoma (PDAC), showing an 82% objective response rate with zoldonrasib plus modified FOLFIRINOX in first-line treatment. The company is advancing two simultaneous Phase

Tone
Positive 71/100
Event
Market update
Published
03 Jul 2026 06:39
Source
The Clinical Trial Vanguard
Simply Wall Street Direct company coverage

Revolution Medicines (RVMD) Reports Phase 1 2 Pancreatic Cancer Data That Sets Up Phase 3

Revolution Medicines (RVMD) has reported promising Phase 1/2 trial data for its RAS(ON) inhibitor combinations, zoldonrasib and daraxonrasib, in metastatic pancreatic cancer. The data showed strong antitumor activity and manageable safety, particularly in patients with RAS G12D m

Tone
Positive 77/100
Event
Market update
Published
03 Jul 2026 03:10
Source
Simply Wall Street
Investing.com Direct company coverage

Revolution Medicines sees large block trade worth $196.7 million

Revolution Medicines Inc. experienced a large block trade of 1.06 million shares, representing 0.5% of its float, valued at $196.7 million. The transaction took place at a 1.3% discount from the opening price. Despite a 0.9% decline on the day of the trade, the stock has gained 1

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 19:10
Source
Investing.com
Investing.com Direct company coverage

Revolution Medicines reports trial results for pancreatic cancer drug

Revolution Medicines Inc. announced positive results from two Phase 1/2 clinical trials for zoldonrasib in combination regimens for RAS G12D metastatic pancreatic ductal adenocarcinoma. The trials showed promising objective response rates and progression-free survival, supporting

Tone
Positive 74/100
Event
Earnings
Published
02 Jul 2026 13:13
Source
Investing.com
grafa.com Direct company coverage

Revolution Medicines reports zoldonrasib pancreatic cancer data

Revolution Medicines reported a high treatment response rate of up to 82% for its zoldonrasib combinations in patients with RAS G12D metastatic pancreatic cancer, causing company shares to rise. These Phase 1/2 data, presented at the ESMO GI 2026 Congress, support the initiation

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 13:13
Source
grafa.com